RFA-AG-25-024: Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 7, 2024.
From the official notice on Grants.gov, last changed May 16, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR61 / R33
- Clinical trialsNot allowed
- Funded byNIA
- Median yearly award$1.8 million
- Typical project length2 years
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under RFA-AG-25-024 were run by National Institute on Aging (NIA, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AG-25-024 in the NIH Guide.
Key dates
| Posted | May 16, 2024 |
|---|---|
| Deadline | October 7, 2024 |
| Archived by Grants.gov | November 12, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (73% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity (NOFO) invites applications proposing innovative strategies to target and manipulate brain cell subtypes that are altered in aging, Alzheimer's Disease (AD), and AD-Related Dementias (ADRDs). ADRDs include frontotemporal disorders (FTD), Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). Specifically, the goal of the NOFO is to encourage the development and utilization of sophisticated tools that pair breakthroughs in adeno-associated virus (AAV) capsid engineering with enhancer element identification to (1) optimize precise targeting of disease-relevant cell subtypes in aged and degenerating mammalian brains and (2) monitor and/or manipulate these cells in vivo to address mechanistic hypotheses related to brain aging and AD/ADRD in animals models. To achieve this goal, the NOFO utilizes the R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for pilot activities to demonstrate proof-of-principle. The R33 phase provides up to 3 years of support for implementation activities including hypothesis testing.
Funded under RFA-AG-25-024 so far
NIH funded 6 projects under RFA-AG-25-024 in fiscal 2025, at 6 institutions. The median yearly award was $1.8 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Enhancer AAV-based genetic access and manipulation of specific brain cell types implicated in aging and Alzheimer's Disease | University of California-Irvine | 2025 | $2.2 million |
| AAV Vectors for Oligodendrocyte Precursor Cells (OPCs) | Johns Hopkins University | 2025 | $1.1 million |
| Magnetogenetic control of vulnerable brain cell types in Alzheimer's disease | University of California Berkeley | 2025 | $2.3 million |
| In vivo single-cell analysis of Alzheimer's disease-associated regulatory elements | Univ of North Carolina Chapel Hill | 2025 | $1.2 million |
| AAV-mediated Interrogation of the Brain FSH Receptor | Icahn School of Medicine at Mount Sinai | 2025 | $2.1 million |
| Enhancer-AAVs to monitor and restore cell-type selective inhibitory deficits and circuit dysfunction in humanized Alzheimer's disease models | J. David Gladstone Institutes | 2025 | $1.5 million |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AG-25-024 still open?
No. It closed on October 7, 2024.
Who can apply for Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)?
Closed October 7, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-AG-25-024?
NIH RePORTER lists 6 projects funded under RFA-AG-25-024 in fiscal 2025, at 6 institutions. The most were at University of California-Irvine, Johns Hopkins University, University of California Berkeley.
Who has won Aging Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, The Trustees of Columbia University in the City of New York, University of Southern California. The program made 11,026 awards worth $19 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)